🇺🇸 FDA
Pipeline program

PIVEKIMAB SUNIRINE

M25-692

Phase 1 small_molecule active

Quick answer

PIVEKIMAB SUNIRINE for Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia is a Phase 1 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Relapsed or Refractory Acute Myeloid Leukemia; Acute Myeloid Leukemia, Acute Myeloid Leukemia
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials